Amendment No. 2 to the Respiratory Diseases Research Collaboration and License AgreementRespiratory Diseases Research Collaboration and License Agreement • August 7th, 2014 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This Amendment No. 2 to the Respiratory Diseases Research Collaboration and License Agreement (this “Amendment No. 2”), effective as of April 9, 2014 (the “Amendment No. 2 Effective Date”), is made by and between Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080 (“FivePrime”).
Amendment No. 1 to the Research Collaboration and License AgreementResearch Collaboration and License Agreement • August 7th, 2014 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to the Research Collaboration and License Agreement (this “Amendment”), effective as of June 5, 2014 (the “Amendment Effective Date”), is made by and between UCB Pharma S.A., a Belgium corporation (“UCB”), and Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”).
